Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OGX-427 + docetaxel
- Development stage
- Phase 2
- Lead developer
- Achieve Life Sciences
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
OGX-427 + docetaxel is a combination therapy consisting of OGX-427 (also known as apatorsen), a second-generation antisense oligonucleotide targeting heat shock protein 27 (HSP27), and docetaxel, a taxane-class cytotoxic chemotherapy. OGX-427 inhibits HSP27 expression, which is known to contribute to cancer cell survival, chemoresistance, and disease progression. By suppressing HSP27, OGX-427 promotes apoptosis and enhances the efficacy of chemotherapeutic agents including docetaxel. The combination has been studied in advanced solid tumors, most notably in metastatic castration-resistant prostate cancer, as well as in urothelial cancer and other settings. In published clinical trials, the combination showed evidence of antitumor activity, including partial responses and PSA declines, and was generally well tolerated with infusion reactions being the primary dose-limiting toxicity[3][4][8].
- Other names
- OGX-427 + docetaxelapatorsen + docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))HSPB1 (Heat shock protein beta-1)
Beyond the preview
Go deeper on OGX-427 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OGX-427 + docetaxel.